Table 1. Overview of dual LAMA/LABA fixed combination currently approved.

Drug	Company	Dosage/Regimen
Glycopyrronium/Indacaterol	Novartis	43/85 μg once-daily (EU, Japan)
		15.6/27.5 µg twice-daily (USA) via SDDPI
Umeclidinium/Vilanterol	GSK	62.5/25 µg once-daily via MDDPI
Tiotropium/Olodaterol	Boehringer Ingelheim	5/5 µg once-daily via Soft Mist Inhaler
Aclidinium/Formoterol	AstraZeneca	340/12 µg twice-daily via MDDPI

LAMA: long-acting antimuscarinics; LABA: long-acting β2-agonists; SDDPI: single dose dry powder inhaler; MDDPI: multi dose dry powder inhaler.